Generated by AI
Aeon Biopharma, Inc. Class A Common Stock represents the equity of Aeon Biopharma, Inc., a biopharmaceutical company focused on developing botulinum toxin-based therapies for therapeutic use. The company’s current work centers on ABP-450 (prabotulinumtoxinA), a botulinum toxin product candidate being studied for medical conditions such as cervical dystonia and migraine. Its business is concentrated on advancing injectable treatments for debilitating disorders and building a portfolio around toxin-based therapeutics. Aeon Biopharma operates in the healthcare and biotechnology sectors, where it plays the role of a specialized clinical-stage developer working to expand treatment options in neurology and related therapeutic areas. Based in Irvine, California, the company’s Class A common stock provides public market exposure to its ongoing research, development, and commercialization efforts in the biopharmaceutical market.
Website5 Park Plaza
Irvine, CA, 92614
United States
The latest articles about AEON.
Detailed price information for Aeon Biopharma Inc (AEON-A) from The Globe and Mail including charting and trades.
Summary of Oct 13's posts. Generated by AI.
Summary of Sep 10's posts. Generated by AI.
Summary of Sep 10's posts. Generated by AI.
Summary of Sep 30's posts. Generated by AI.
Investors talking about AEON also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.